前收市價 | 0.0500 |
開市 | 0.0500 |
買盤 | 0.0000 |
賣出價 | 1.5000 |
拍板 | 10.00 |
到期日 | 2024-10-18 |
今日波幅 | 0.0500 - 0.0500 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 13 |
Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.